Merck Report Result of Keytruda (pembrolizumab) + Lenvima (lenvatinib) as 1L Treatment for Advanced Renal Cell Carcinoma
Shots:
- The P-III CLEAR study involves assessing of Lenvima (20 mg/day) + Keytruda (200 mg- IV- q3w) or in combination with everolimus (5mg- qd) vs sunitinib (50 mg- q4w) in 1-069 patients for the 1L treatment with advanced RCC
- The trial met its 1EPs with Keytruda + Lenvima shows 61% reduction in the risk of disease progression or death- mPFS (2yrs. vs 9 mos.) 2 EPs shows 34% reduced the risk of death- ORR (71.0% vs 36.1%); CR (16.1 vs 4.2%); PR( 54.9% vs 31.9%); mDoR(25.8 vs 14.6mos)
- Lenvima + everolimus shows 35% reduction in the risk of disease progression or death; mPFS (14.7 vs 9.2mos); CR (9.8% vs 4.2%); PR (43.7% vs 36.1%); mDOR (16.6 vs 14.6 mos.)@median follow-up 27 mos.
Ref: Merck | Image: Merck
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com